Jasper Therapeutics Announces Appointment Of Thomas G. Wiggans As Chairperson Of The Board Of Directors
Portfolio Pulse from Benzinga Newsdesk
Jasper Therapeutics, Inc. (NASDAQ:JSPR) has appointed Thomas G. Wiggans, a veteran biopharmaceutical executive, as Chairperson of its Board of Directors. Wiggans has served in senior leadership positions at multiple successful biopharmaceutical companies, including Dermira (NASDAQ:DERM), which was acquired by Eli Lilly in 2020. The current Chairperson, Bill Lis, will retire from the Board in December.
November 01, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The appointment of Thomas G. Wiggans as Chairperson of Jasper Therapeutics' Board of Directors could bring valuable experience and leadership to the company, potentially benefiting its strategic direction and growth.
Thomas G. Wiggans' extensive experience in the biopharmaceutical industry, including his tenure at Dermira, could provide valuable insights and leadership for Jasper Therapeutics. This could potentially influence the company's strategic direction and growth, positively impacting its stock.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
Thomas G. Wiggans, former Chairman and CEO of Dermira, has been appointed as Chairperson of Jasper Therapeutics' Board of Directors. Dermira was acquired by Eli Lilly in 2020.
While the news mentions Dermira, the company was acquired by Eli Lilly in 2020 and therefore this news is unlikely to have a direct impact on its stock.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50